FidoCure® Veterinary Team Blog
Read the latest in veterinary oncology research and FidoCure® scientific and clinical updates from our team of experts and advisors
Hemangiosarcoma: Advancing canine cancer treatment with targeted therapies
Canine cancer diagnoses can be devastating and demoralizing. While research and studies for human cancer have brought us a long way when it comes to treatment and instilling hope for our loved ones, the same can’t necessarily be said for the world of pet medicine. Despite this, there are many passionate veterinarians and vet oncologists out there who are helping to move the needle on pet cancer research and treatment. Taking cues from the progress made on human cancer treatment, FidoCure uses genomic testing to match dogs with targeted therapies for their specific cancer profile. Not only does this process increase the chances of a better prognosis, but it helps vets and vet oncologists deduce effective therapies for future canine cancer cases. FidoCure has already proven that a prognosis can be improved using targeted therapies. Take hemangiosarcoma for instance…
Splenic Hemangiosarcoma Case Study: Pita
With a combination approach that included FidoCure® therapy, Pita lived for a year following a hemoabdomen and diagnosis of splenic hemangiosarcoma.
Research featured in The Cancer Letter
We were thrilled to see our recent Nature paper featured in last week's issue of The Cancer Letter! Our multi-year study has compared canine and human cancer journeys...
TCC Case Study: Sir Oliver
Sir Oliver, an 8 year old French Bulldog with TCC, is surviving and thriving thanks to his targeted therapeutic treatment4.5 months from FidoCure™ enrollment, Sir Oliver's latest CT scan showed a 38% reduction in his bladder tumor.
Mammary Carcinoma Case Study: Missy
After one year of FidoCure®targeted therapy, Missy showed no evidence of pulmonary metastatic disease.
Squamous Cell Carcinoma Case Study: Duchess
It is clear that the utilization of targeted therapy has proven beneficial in improving patient quality of life, extending survival time with minimal disease progression, and having an overall positive impact on patient care.
Lung Carcinoma Case Study: Adley Hurwitz
After six months of FidoCure® enabled therapy, Adley showed no evidence of pulmonary mass recurrence.